Co-occurrence of amikacin-resistant and -susceptible mycobacterium tuberculosis isolates in clinical samples from Beijing, China

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1537-1542

  Zhang, Xiaobing ^a   Zhao, Bing ^b   Huang, Hairong ^c   Zhu, Yafang ^a   Peng, Junping ^a   Dai, Guangming ^c   Jiang, Guanglu ^c   Liu, Liguo ^a   Zhao, Yanlin ^b   Jin, Qi ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Aminoglycoside antibiotics; heteroresistance; MDR TB; Molecular typing

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; GOLD; KANAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; CHINA; CONTROLLED STUDY; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 84879483200     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt082     Document Type: Article

References (26)

1. WHO. Global Tuberculosis Control: WHO Report 2011. Geneva: WHO, 2011.
2. WHO. The Stop TB Department. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva: WHO, 2008.
3. Liu CH, Li L, Chen Z et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS ONE 2011; 6: e19399.
4. Han LL, Sloutsky A, Canales R, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005; 9: 818-21.
5. Rinder H, Mieskes KT, Loscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2001; 5: 339-45.
6. Streicher EM, Bergval I, Dheda K, et al. Mycobacterium tuberculosis population structure determines the outcome of genetic based second-line drug resistance testing. Antimicrob Agents Chemother 2012; 56: 2420-7.
7. Hofmann-Thiel S, van Ingen J, Feldmann K, et al. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 2009; 33: 368-74.
8. Cullen MM, Sam NE, Kanduma EG, et al. Direct detection of heteroresistance in Mycobacterium tuberculosis using molecular techniques. J Med Microbiol 2006; 55: 1157-8.
9. Zhang X, Zhao B, Liu L, et al. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. J Clin Microbiol 2012; 50: 1471-4.
10. Sander P, Prammananan T, Bottger EC. Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol Microbiol 1996; 22: 841-8.
11. Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1295-7.
12. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-7.
13. Jugheli L, Bzekalava N, de Rijk P, et al. High level of crossresistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53: 5064-8.
14. Laszlo A, Rahman M, Raviglione M, et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/ IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1: 231-8.
15. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-78.
16. Suzuki Y, Katsukawa C, Tamaru A, et al. Detection of kanamycinresistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998; 36: 1220-5.
17. Kruuner A, Jureen P, Levina K, et al. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 2971-3.
18. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990; 93: 125-8.
19. Weniger T, Krawczyk J, Supply P, et al. MIRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res 2010; 38: W326-31.
20. Liu Q, Yang D, Xu W, et al. Molecular typing of Mycobacterium tuberculosis isolates circulating in Jiangsu province, China. BMC Infect Dis 2011; 11: 288.
21. Sirgel FA, Tait M, Warren RM, et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 2012; 18: 193-7.
22. Baldeviano-Vidalon GC, Quispe-Torres N, Bonilla-Asalde C, et al. Multiple infection with resistant and sensitive M. tuberculosis strains during treatment of pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2005; 9: 1155-60.
23. Falagas ME, Makris GC, Dimopoulos G, et al. Heteroresistance: a concern of increasing clinical significance?. Clin Microbiol Infect 2008; 14: 101-4.
24. Blaschitz M, Hasanacevic D, Hufnagl P, et al. Real-time PCR for single-nucleotide polymorphism detection in the 16S rRNA gene as an indicator for extensive drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 66: 1243-6.
25. Bouakaze C, Keyser C, Gonzalez A, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based single nucleotide polymorphism genotyping assay using iPLEX gold technology for identification of Mycobacterium tuberculosis complex species and lineages. J Clin Microbiol 2011; 49: 3292-9.
26. He GX, van den Hof S, Borgdorff MW, et al. Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a situational analysis. Int J Tuberc Lung Dis 2010; 14: 884-9.